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ABSTRACT  
A hierarchical prognostic model for risk stratification in patients with early 
breast cancer according to 
18
F-fluorodeoxyglucose uptake and 
clinicopathological parameters 
 
Jong Tae Cha 
 
Department of Medicine 
The Graduate School, Yonsei University 
 
(Directed by Professor Mijin Yun) 
 
Purpose: The purpose of this study was to investigate the prognostic value of 
18
F-
fludeoxyglucose (FDG) uptake in the primary tumor on positron emission 
tomography/computed tomography (PET/CT) for recurrence-free survival (RFS), as 
well as interactions between clinicopathological and metabolic prognostic factors for 
risk stratification in patients with early stage breast cancer who underwent surgery 
without neoadjuvant chemotherapy. 
Methods: Between January 2008 and December 2013, 524 patients with early stage 
breast cancer who had undergone 
18
F-FDG PET/CT for initial staging and surgery 
without neoadjuvant treatment were included. The Cox proportional hazards model 
for RFS was used with clinicopathological variables and maximum standardized 
uptake value (SUVmax) on PET/CT. After classification and regression tree (CART) 
2 
 
modeling, RFS curves were estimated using the Kaplan-Meier method and differences 
in each risk layer were assessed using the log rank test. 
Results: During a median follow-up duration of 46.2 months, 31 (5.9%) patients 
experienced recurrence (8 loco-regional recurrence, 23 distant metastases). In 
univariate analysis, SUVmax (>6.75), tumor size (>2.0 cm), and triple negative (TN) 
subtype were significant for RFS. In multivariate analysis, SUVmax was the only 
independent prognostic factor for RFS (p=0.028). The CART model identified 4 risk 
layers: group 1 (SUVmax 6.75 and tumor size 2.0 cm); group 2 (SUVmax 6.75, 
tumor size >2 cm, and Luminal A [LumA] or TN); group 3 (SUVmax 6.75, tumor 
size >2.0 cm, and Luminal B [LumB] or human epidermal growth factor receptor 2 
[HER2]-enriched]); group 4 (SUVmax >6.75). Five-year RFS was as follows: 95.9% 
(group 1), 98% (group 2), 82.8% (group 3), and 85.4% (group 4). Group 3 or 4 
showed worse prognosis than group 1 or 2 (group 1 vs. group 3: p=0.040 after 
adjustment; group 1 vs. group 4: p<0.001 after adjustment; group 2 vs. group 3: 
p=0.016 after adjustment; group 2 vs. group 4: p<0.001 after adjustment). 
Conclusion: High SUVmax (>6.75) in primary breast cancer was an independent 
prognostic factor for poor RFS. In patients with low SUVmax, LumB or HER2-
enriched subtype tumor >2 cm was also a prognostic factor for poor RFS, similar to 
high SUVmax. 
 
 
 
 
 
---------------------------------------------------------------------------------------- 
Key words: early breast cancer, risk model, 
18
F-FDG PET/CT, recurrence free 
survival  
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Ι. INTRODUCTION 
Breast cancer is the most common malignancy among women worldwide.
1
 Due to 
increased screening, the majority of patients present with early stage disease.
2
 
Treatment of choice in early breast cancer (stage 0, I, and, II) is surgical resection 
followed by adjuvant chemotherapy according to clinicopathological risk factors.
3, 4
 
The known prognostic factors are axillary nodal status, tumor size, tumor pathology, 
tumor grade, peritumoral lymphatic vessel and vascular invasion, hormonal receptors, 
proliferation markers, ethnicity, and age, among others.
5
 In addition, five intrinsic 
subtypes based on gene expression profiles have shown distinct tumor phenotypes in 
predicting patient outcomes.
6, 7
 Genomic risk stratification has been also useful in 
selecting patients who would benefit from adjuvant chemotherapy.
8
 Due to limitations 
preventing the routine use of gene expression profiling, immunohistochemistry (IHC) 
staining for hormonal receptors and human epidermal growth factor receptor 2 (HER2) 
has been preferred as a therapy-oriented surrogate of intrinsic subtype.
9, 10
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18
F-fluorodeoxyglucose (FDG) positron emission tomography/computed 
tomography (PET/CT) has advantages over conventional imaging modalities in that it 
offers non-invasive, semi-quantitative information about metabolically active tumor 
burden, tumor biology, and patient prognosis.
11-13
Unlike pathological and genomic 
prognostic factors, clinically relevant information can be provided in preoperative 
settings with potential therapeutic implications. Although maximum standardized 
uptake value (SUVmax) in primary breast cancer has been found to be an independent 
prognostic factor for survival, studies have included patient populations with different 
risks for recurrence by including both early and locally advanced cancers, with or 
without neoadjuvant chemotherapy. Nevertheless, a risk stratification model using 
metabolic variables on PET/CT combined with other known prognostic factors has 
not been proposed. 
The purpose of this study was to investigate the prognostic value of 
18
F-FDG 
uptake in the primary tumor for recurrence-free survival (RFS) in patients with early 
breast cancer who underwent surgery without neoadjuvant chemotherapy. In addition 
to conventional statistical modeling of prognosis, a hierarchical prognostic system 
was applied to identify further synergistic/antagonistic interactions between 
clinicopathological prognostic factors and 
18
F-FDG uptake. 
 
II. MATERIALS AND METHODS 
1. Patients  
Data from patients with breast cancer who underwent 
18
F-FDG PET/CT at initial 
staging between January 2008 and December 2013 were retrieved from the 
institutional medical database. Patients were included if they had pathologically 
proven breast cancer and IHC results for estrogen receptor (ER), progesterone 
receptor (PR), HER2, and Ki-67 status. To be included, patients also had to have 
undergone mastectomy with sentinel lymph node dissection and/or axillary lymph 
node dissection without neoadjuvant treatment. Among these(n=672), patients with 
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locally advanced breast cancer (N2/3 classified according to 7th edition of American 
Joint Committee on Cancer [AJCC])
14
 were excluded(n=19). Tumors <1 cm in size 
were excluded to minimize a partial-volume averaging effect affecting semi-
quantitative measurement of 
18
F-FDG uptake(n=103). Patients who had bilateral 
breast cancers were excluded (n=11). Patients visited the hospital every 3 months for 
the first year of follow-up. Routine examinations, including breast sonography, and 
whole body bone scan, were performed every 6 months for the first year and annually 
thereafter. Mammography was performed annually. Whenever abnormal findings 
were noted, further diagnostic studies were performed for confirmation. Patients 
without regular follow-up data were excluded(n=15). Finally, 524 patients were 
included in the analysis. This study was approved by the Institutional Review Board 
of our Hospital. Given the retrospective nature of this study and the use of 
anonymized data, the requirement for informed consent was waived.  
 
2. PET/CT Imaging  
PET/CT was performed using a scanner (Discovery STE; GE Healthcare, 
Milwaukee, WI or Biograph TruePoint 40; Siemens Medical Systems, Knoxville, TN) 
with 16- or 40-slice CT, respectively. Patients fasted for at least 6 h before imaging, 
and glucose levels in the peripheral blood were ≤140 mg/dL before the injection of 
18
F-FDG. An 
18
F-FDG dose of approximately 5.5 MBq/kg was administered 
intravenously 1 h before image acquisition. After the initial low-dose CT study 
(Discovery STE, 30 mA, 130 kVp or Biograph TruePoint 40, 36 mA, 120 kVp), a 
standard PET protocol was used to scan from the neck to the proximal thighs with an 
acquisition time of 2.5 min per bed position in the three-dimensional mode. PET 
images were reconstructed using ordered subset expectation maximization with CT 
images for attenuation correction. 
 
3. Measurement of PET Parameters 
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Two experienced nuclear medicine physicians reviewed all PET/CT images; 
discrepancies were resolved by consensus. Metabolic parameters were measured 
using Volume Viewer software (GE Healthcare, USA). For semi-quantitative analysis, 
a volume of interest was drawn for each lesion to measure SUVmax. SUVmax was 
calculated using the following formula: (decay-corrected activity [kBq]/tissue volume 
[mL])/(injected 
18
F-FDG activity [kBq]/body mass [g]). 
 
4. Histological Evaluation and Categorization of Molecular Subtypes 
All patients underwent surgical resection for breast cancer with sentinel lymph 
node biopsy and/or axillary lymph node dissection. Histological type, tumor size, 
tumor grade, and lymphovascular invasion (LVI) status were determined from the 
surgically excised specimens. Tumor, node, and metastasis (TNM) staging was 
performed according to the 7th edition of the AJCC.
14
The histological grade of each 
tumor was determined using the modified Bloom-Richardson classification.
15
 
Formalin-fixed, paraffin-embedded tissue blocks were used for IHC; the expression 
status of ER, PR, HER2, and Ki-67 was determined by IHC staining of the surgical 
specimen. Primary antibodies against ER (Clone SP1; Neomarkers for Lab Vision, 
Fremont, USA), PR (Clone PgR 636; DAKO, Glostrup, Denmark), HER2 (Clone 
Polyclonal; DAKO, Glostrup, Denmark), Ki67 (Clone MIB-1; DAKO, Glostrup, 
Denmark) were used. ER positivity (+) and PR (+) was defined as the presence of ≥1% 
positively stained nuclei in 10 high-power fields. HER2 staining was analyzed 
according to the American Society of Clinical Oncology/College of American 
Pathologists guidelines.
16
The intensity of HER2 staining was scored as 0, 1+, 2+, or 
3+. Tumors with a 3+ score were considered to be HER2 (+), whereas those with a 0 
or 1+ score were considered to be HER2 negative (−). Tumors with a 2+ score were 
subjected to fluorescence in situ hybridization analysis to determine HER2 status. For 
Ki-67, nuclear staining ≥14% was considered to be high-level expression. According 
to different combinations of ER, PR, HER2 and Ki-67, the patients were categorized 
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into four different molecular subtypes as follows: Luminal A (LumA): ER (+) and/or 
PR (+), HER2 (−), and Ki-67 low (<14 %); Luminal B (LumB): ER (+) and/or PR (+), 
HER2 (−), and Ki-67 high (≥14%) or ER (+) and/or PR (+), HER2 (+), and any Ki-
67 index; HER2-enriched: ER (−), PR (−), but HER2 (+); and Triple negative (TN): 
ER (−), PR (−), and HER2 (−). 
 
5. Statistical Analysis 
RFS was defined as the time from the operation date to the date of cancer 
recurrence. The prognostic values of clinicopathological factors, including age, tumor 
size, nodal status, TNM stage, histologic type, histologic grade, LVI, molecular 
subtypes, proliferation index, treatment modalities, and SUVmax, were assessed using 
a Cox proportional hazards model for RFS. Hazard ratio (HR) with Wald 95% 
confidence intervals (CI) were provided for the model. All continuous variables were 
grouped into two categories according to the optimal cut-off values determined using 
receiver-operating characteristic (ROC) curve analysis. Multi-collinearity among 
independent variables was evaluated using Spearman rank correlation coefficient 
before multivariate analysis.  
Next, to identify further synergistic/antagonistic interactions between prognostic 
factors, a classification and regression tree (CART) was generated for RFS. Left 
truncated and right censored (LTRC) CART is a prognostic system with a hierarchical 
structure based on recursive partitioning that builds a decision tree to find subgroups 
at higher risk for recurrence. Factors that were statistically significant in univariate 
analyses were included in the CART analysis. Each node on the decision trees 
included subgroups of a population with common characteristics influencing RFS. 
HRs of each groups elicited by CART model were assessed using Cox proportional 
hazard model. Finally, cumulative RFS curves of each risk layer were estimated using 
the Kaplan-Meier method, and the statistical differences among the risk layers were 
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compared using the log rank test with pairwise comparison to account for multiple 
comparison correction. 
All statistical analyses were performed using SPSS version 23 (IBM Corporation, 
Armonk, NY, USA) for Windows (Microsoft Corporation, Redmond, WA, USA) and 
R 3.33.0 software (The R Foundation for Statistical Computing, Vienna, Austria) with 
necessary analytical packages such as LTRC trees, rpart and survival; p<0.05 was 
considered to be statistically significant. 
 
III. RESULTS 
1. Patient Characteristics 
The clinicopathological characteristics of the 524 female patients (median age 50 
years [range, 27–82 years]) are summarized in Table 1. There were 270/524 (51.5%) 
patients with TNM stage I and 254/524 (48.5%) with stage II cancer. Of the 125/524 
(23.9%) patients with lymph node metastasis (N1), 23/524 (4.4%) had known N1 
metastasis according to ultrasonography-guided biopsy before surgery, and 102/524 
(19.5%) exhibited lymph node metastasis only by sentinel lymph node sampling. 
There were 225/524 (42.9%) patients with LumA, 155/524 (29.6%) with LumB, 
42/524 (8.0%) with HER2-enriched, and 102/524 (19.5%) with TN subtypes. The 
mean SUVmax of the primary tumors was 5.51 ± 4.10. 
During a median follow-up duration of 46.2 months (range, 5.4–95.2 months), 
31/524 (5.9%) patients experienced recurrence (8 loco-regional recurrence, 23 distant 
metastasis). Fourteen of the 270 patients with stage I and 17 of the 254 patients with 
stage II cancer had recurrence. According to molecular subtype, there was recurrence 
in 8/225 (3.6%) with LumA, 10/155 (6.5%) with LumB, 4/42 (9.5%) with HER2-
enriched, and 9/102 (8.8%) with TN. 
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Table 1.Patient Characteristics  
Variable  
Age (y)
1 
50 (27 - 82) 
SUVmax (g/ml) 5.51 ± 4.10 
Tumor size (cm)  1.92 ± 0.79 
Nodal status (n)  
Negative 399 (76.1%) 
Positive  
Sentinel LN positive 102 (19.5%) 
Axillary LN positive 23 (4.4%) 
TNM stage (n)  
I/II 270 (51.5%)/254 (48.5%) 
Histologic type (n)  
IDC/ILC/Other
2
 457 (87.2%)/16 (3.1%)/51 (9.7%) 
Histologic grade (n)  
1/2/3 110 (21.0%)/240 (45.8%)/174 (33.2%) 
Lymphovascular invasion (n)  
Negative/Positive 465 (88.7%)/59 (11.3%) 
Ki67 (%) 21.78 ± 21.70 
Molecular subtype (n)  
LumA/LumB/HER2-
enriched/TN 
225 (42.9%)/155 (29.6%)/42 (8.0%)/102 (19.5%) 
Adjuvant chemotherapy (n)  
Done/Not done 430 (82.1%)/94 (17.9%) 
1
Median value (range) 
2
Other: primary breast cancer other than Invasive Ductal Carcinoma (IDC) or Invasive 
Lobular Carcinoma (ILC). 
Data are reported as mean with standard deviation unless otherwise specified. 
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2. Clinicopathological and Imaging Prognostic Factors for RFS 
Optimal cut-off values for SUVmax and size were >6.75 and >2.0 cm, respectively. 
In univariate analysis, SUVmax (>6.75), size (>2.0 cm), and TN subtype were 
significant prognostic factors for RFS. In multivariate analysis, SUVmax was the only 
independent prognostic factor for RFS (HR 2.6 [CI, 1.1-6.1]; p=0.028) (Table 2).   
11 
 
 
Table 2 Univariate and Multivariate Analysis of Recurrence free Survival 
Variable 
Univariate analysis Multivariate analysis 
P-value 
Hazard ratio (95% 
CI) 
P-value 
Hazard ratio (95% 
CI) 
Age 
(35 vs. >35 y) 
0.699 0.75 (0.17-3.16)   
SUVmax 
(6.75 vs. >6.75) 
0.001 3.50 (1.69-7.23) 0.028 2.60 (1.10-6.14) 
Tumor size 
(2cm vs. >2cm) 
0.019 2.33 (1.15-4.74) 0.205 1.63 (0.76-3.46) 
Nodal status  
(Negative vs. 
Positive) 
0.750 0.74 (0.30-1.82)   
TNM Stage  
(I vs. II) 
0.544 1.24 (0.61-2.52)   
Histologic type 
IDC 
ILC 
  Other
1
 
 
 
0.97 
0.52 
 
 
0.00 
1.40 (0.49-4.02) 
  
Histologic grade  
(1 or 2 vs. 3) 
0.327 1.42 (0.70-2.91)   
LVI 
(Negative vs. 
Positive) 
0.830 1.13 (0.39-3.24)   
Ki67 
(14% vs. >14%) 
0.054 2.09 (0.98-4.45)   
Molecular subtype 
LumA 
LumB 
  HER2-enriched 
  TN 
 
 
0.183 
0.108 
0.046 
 
 
1.18 (0.74-4.76) 
2.67 (0.80-8.91) 
2.63 (1.01-6.83) 
 
 
0.658 
0.529 
0.579 
 
 
1.24 (0.46-3.33) 
1.51 (0.41-5.49) 
1.35 (0.46-3.91) 
Adjuvant 
chemotherapy 
(Done vs. Not 
done) 
0.483 1.45 (0.50-4.16)   
1
Other: primary breast cancer other than IDC or ILC. 
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3. Risk Stratification Using CART Analysis  
CART modeling was performed using statistically significant variables found in the 
univariate analysis to identify subgroups at higher risk for recurrence. Accordingly, 
SUVmax >6.75, tumor size >2.0 cm, and molecular subtypes were included in CART 
analysis. The resulting CART model revealed 4 risk layers based on SUVmax, tumor 
size, and molecular subtype: group 1 (SUVmax 6.75 and tumor size 2.0 cm); group 
2 (SUVmax 6.75, tumor size >2.0 cm, and LumA or TN); group 3 (SUVmax 6.75, 
tumor size >2.0 cm, and LumB or HER2-enriched); group 4 (SUVmax >6.75) (Figure 
1). There were 278 (53%) patients in group 1, 52 (10%) in group 2, 33 (6%) in group 
3, and 161 (31%) in group 4. LumA was the most common subtype in group 1 and TN 
was the most common in group 4. 
 
4. Kaplan-Meier Survival Analysis in 4 Risk Layers on CART Modeling 
According to the risk layers, the 5-year RFS was 95.9% in group 1, 98% in group 2, 
82.8% in group 3, and 85.4% in group 4 (Figure 1). Groups 3 or 4 demonstrate worse 
prognosis than groups 1 or 2 (group 1 vs. group 3: p=0.040 after adjustment; group 1 
vs. group 4: p<0.001 after adjustment; group 2 vs. group 3: p=0.016 after adjustment; 
group 2 vs. group 4: p<0.001 after adjustment). No significant difference in RFS was 
observed between patients in group 1 and those in group 2 (p=0.553 after adjustment). 
The patients in group 3 showed no remarkable difference in RFS compared with those 
in group 4 (p=0.847 after adjustment). 
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Fig 1. Classification and regression tree analyses to identify synergistic/antagonistic 
associations between prognostic factors. Square boxes indicate, respectively, 
intermediate and terminal subsets of patients defined by the sequential splitting 
process. There are 4 terminal risk groups. The numbers after molecular subtype are 
the number of recurrences of the total number of patient in each subtype. Cox 
proportional hazard model calculated HRs of each groups. * = statistically significant 
difference for pairwise comparison using log rank test. HER2 = human epidermal 
growth factor receptor 2; LumA = Luminal A; LumB = Luminal B; TN = triple 
negative.  
14 
 
IV. DISCUSSION 
Because the majority of patients with breast cancer present at an early stage of 
disease, we included only a large population of stage I and II breast cancer patients 
who underwent upfront surgery without neoadjuvant chemotherapy.
2, 3
 High SUVmax 
(> 6.75) in the primary tumor was the only independent prognostic factor for RFS in 
multivariate analysis. Other than SUVmax, tumor size and molecular subtype were 
significant in univariate analysis. In general, nodal status seems to be the most 
powerful prognostic factor for RFS in early stage breast cancer.
17, 18
 Regardless, it was 
not prognostic for RFS in this study. There were 125/524 (23.9%) patients with N1 
metastasis, in which only a small number (n=23/524 [4.4%]) had N1 metastasis 
confirmed before surgery. The remaining 102/524 (19.5%) patients had N1 disease 
according to sentinel lymph node sampling. Most N1 metastasis was not clinically 
detectable, and improved surgical removal of metastatic lymph nodes and effective 
adjuvant therapy may have contributed to the result. 
SUVmax at staging has been prognostic for RFS in patients with operable breast 
cancer.
19-25
 However, no studies have evaluated the interactions between 
clinicopathological and metabolic prognostic factors for risk stratification. We used 
CART analysis to evaluate high-order associations among the significant factors in 
univariate analysis for further risk stratification. SUVmax >6.75, tumor size >2.0 cm, 
and molecular subtypes were included in the analysis, resulting in 4 different risk 
layers. Among the 4 risk groups based on CART modeling, patients in groups 3 and 4 
showed no significant difference in 5-year RFS rates (82.8% and 85.4%, respectively). 
Patients in groups 1 and 2 also showed no difference in 5-year RFS rates (95.9% and 
98%, respectively). The 5-year RFS rates in groups 3 or 4 were significantly worse 
than those in groups 1 or 2. 
As expected in multivariate analysis, high SUVmax was the highest-order risk 
factor for RFS on CART modeling. In group 4 (SUVmax >6.75), neither size nor 
molecular subtype was significant for further risk classification. This group 
15 
 
demonstrated a higher HR (7.29) for RFS. In the remaining patients (groups 1, 2, and 
3) with low SUVmax (6.75), tumor size was the next classification factor. Patients 
with a tumor size 2 cm represented a separate risk layer with a lower HR (1.36) for 
RFS (group 1). In patients with tumor size >2 cm, there were two different risk layers 
according to molecular subtype. In patients with LumA or TN subtypes (group 2), the 
HR (1.00) was similar to that of group 1, whereas it was 8.67 in patients with LumB 
or HER2-enriched subtypes (group 3), similar to that of group 4. Similar to high 
SUVmax, LumB or HER2-enriched breast cancers >2 cm appeared to be important in 
predicting worse RFS in patients with low SUVmax. 
TN breast cancer is known to demonstrate the worst survival, whereas LumA has 
the best survival.
26
 However, there were interesting risk stratification patterns in 
patients with TN or LumA subtype in this study. Despite the known poor prognosis of 
the TN subtype, of the 102 patients with TN, 39 (38%) with low SUVmax showed 
significantly better RFS than the remaining 63 (62%) patients with high SUVmax. In 
contrast to LumB or HER2-enriched, tumor size was not prognostic in TN when 
SUVmax was low. Given that TN subtype demonstrates heterogeneous histology as 
well as gene expressions
27
, SUVmax appeared to have potential in differentiating 
patients with different risks for RFS in TN subtype.  
In the LumA subtype, there is a high clinical demand for techniques to identify 
patients who could benefit from toxic adjuvant chemotherapy. Oncotype DX assay 
(Genomic Health), based on the expression of 21 genes, has been useful in scoring the 
likelihood of distant metastasis and aiding in treatment decisions 
28
. In this study, only 
23 (10.2%) of the 225 patients with LumA demonstrated high SUVmax and worse 
RFS. The remaining 202 (89.8%) patients demonstrated low SUV max and better RFS. 
Similar to the TN subtype, tumor size was not prognostic in LumA when SUVmax 
was low. Further studies are needed to determine the value of SUVmax to predict RFS 
and to select patients for adjuvant chemotherapy in LumA breast cancer. 
The present study had several limitations, the first of which was its retrospective 
16 
 
design. However, we analyzed a large homogenous population of patients with stage I 
and II breast cancer with complete pathological results. Second, we excluded patients 
whose primary tumor diameter was <1 cm to avoid a partial-volume averaging effect 
on SUVmax measurement, which may have resulted in exaggerated prognostic value 
of SUVmax on small size tumors.
29, 30
 Even with partial-volume correction, 
overcorrection can be problematic in tumors with diameters <1.5 times the full-width 
at half-maximum.
31
 Regardless, performing 
18
F-FDG PET/CT in patients with breast 
cancer tumors <1 cm is less likely. 
 
V. CONCLUSION 
In this study, we proposed a risk stratification model using clinicopathological and 
metabolic prognostic factors in stage I and II breast cancer patients who underwent 
surgery without neoadjuvant chemotherapy. High SUVmax (>6.75) in the primary 
tumor was an independent prognostic factor for poor RFS. In patients with low 
SUVmax, LumB or HER2-enriched tumor >2 cm was a poor prognostic factor for 
RFS, similar to high SUVmax. 
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ABSTRACT(IN KOREAN) 
 
조기 유방암 환자의 원발종양 18F-flurodeoxyglucose 섭취와 
임상병리적 인자를 활용한 계층적 예후모델 제시 
 
<지도교수 윤미진> 
 
연세대학교 대학원 의학과 
 
차종태 
 
 
본 연구의 목적은 수술 전 항암 요법을 받지 않은 조기 유방암 환자에서 
양전자 컴퓨터 단층 촬영 영상의 원발종양 18F-fludeoxyglucose 섭취 
정도가 환자의 재발을 예측하는 예후 인자임을 확인하고 더 나아가 
고위험군 환자를 분류하는데 있어 다른 예후 인자들과 어떻게 
상호작용하는지 분석하는 것이다. 
대상 및 방법: 2008년 1월부터 2013년 12월까지 수술 전 항암 요법을 받지 
않은 524 명의 조기 유방암 환자를 모집하였다. 콕스-비례위험모형을 통해 
최대 표준화섭취계수 (SUVmax) 및 임상병리적 인자들 중 환자의 무 재발 
생존과 관련된 예후인자들을 찾았다. 그 후 찾은 인자들을 이용하여 분류 
및 회귀 트리 모델 분석을 시행하고 재발 위험에 따라 환자를 층계화 할 
때 예후 인자들끼리 어떻게 상호작용 하는지를 분석한 예후 모델을 
제시하였다. 마지막으로 카플란마이어법 및 로그순위법을 통해 층계화 된 
그룹들의 생존곡선을 비교하였다.  
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결과: 추적관찰 기간의 중위값은 46.2 개월이었고, 추적관찰 중 재발한 
환자는 총 31명이었다 (국소전이 8명, 원격전이 23명). 일변량 분석에서는 
종양의 SUVmax (>6.75), 크기 (>2.0 cm), 그리고 삼중음성 유형이 나쁜 
예후 인자였다. 그리고 다변량 분석에서는 SUVmax 만이 독립적인 나쁜 
예후 인자였다 (p=0.028). 분류 및 회귀 트리 모델 분석은 재발 위험도에 
따라 환자를 네 그룹으로 나누었다(그룹 1 (SUVmax 6.75 그리고크기2.0 
cm); 그룹 2 (SUVmax 6.75, 크기>2 cm, 그리고루미날 A 또는삼중음성 
유형); 그룹 3 (SUVmax 6.75, 종양의 크기 >2.0 cm, 그리고루미날 B 
혹은상피성장인자 수용체 과발현 유형); 그룹 4 (SUVmax >6.75)). 각 
그룹의 무재발 5년 생존율은 다음과 같았다: 95.9% (그룹 1), 98% (그룹 
2), 82.8% (그룹 3), and 85.4% (그룹 4). 그룹 3 과 그룹 4 는 그룹 1 과 
그룹 2 보다 나쁜 예후를 보였다. 
결론: 조기 유방암 환자에서 원발 종양의 높은 SUVmax 값은 독립적인 나쁜 
예후 인자였다. SUVmax 값이 낮더라도 종양의 크기가 2 cm 이상인 루미날 B 
혹은 상피성장인자 수용체 과발현 유형은 SUVmax 값이 높은 그룹만큼이나 
안 좋은 예후를 보였다.  
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